Defense Biotechnology Strategy Act
- Sponsor
- Rep. Houlahan, Chrissy [D-PA-6]
- Committees
- Foreign Affairs Committee (primary)
- Last action
- Nov 10, 2025
Bottom line
This bill mandates the Department of Defense to create a comprehensive strategy for integrating emerging biotechnologies into national security, focusing on domestic industrial base, regulatory frameworks, and international collaboration.
What it actually does
This bill directs the Secretary of Defense to develop and submit a comprehensive strategy on the national security implications of emerging biotechnologies within one year of enactment. The strategy must address how the Department of Defense will develop biomanufacturing networks, update military specifications, utilize advance market commitments, integrate biotechnology into wargaming, explore research grand challenges, establish a biotechnology regulation science program, and enhance international cooperation with NATO allies.
Proponents argue
Supporters argue this bill is crucial for maintaining the U.S. competitive edge in defense by proactively addressing the national security implications of rapidly advancing biotechnologies. It would ensure the DoD leverages biotech for critical defense needs, fosters a robust domestic biomanufacturing base, and strengthens alliances through coordinated research and procurement.
Opponents contend
Opponents might argue that mandating such a broad strategy could lead to bureaucratic bloat and divert resources from immediate defense priorities. Concerns could also be raised about the potential for over-regulation stifling innovation or the feasibility of coordinating complex biotechnology initiatives across diverse international partners.
The bill is very short and straightforward, making it highly accessible for any reader to understand its core directives.
Section 2(a)
Direction to Develop a National Security Biotechnology Strategy
This section requires the Secretary of Defense, in coordination with the Under Secretaries for Research & Engineering and Acquisition & Sustainment, to submit a strategy within one year. This strategy must address the national security implications of emerging biotechnologies, their future role in defense, and ways to improve relationships with industry, other agencies, and international partners in this sector.
Supporters argue
Supporters argue this provision is essential for proactive defense planning, ensuring the DoD is prepared for future threats and opportunities presented by biotechnology. It forces a comprehensive look at an emerging domain critical for national security.
Critics contend
Critics might suggest that the DoD already has mechanisms for strategic planning and that a specific legislative mandate for a 'strategy on strategy' could be redundant or overly prescriptive, potentially leading to a document that lacks actionable detail.
Tradeoffs
Balances the need for strategic foresight in a rapidly evolving field against the potential for bureaucratic overhead in strategy development.
Section 2(b)(1)
Expanding Commercial Biomanufacturing Facilities
The strategy must detail how the Department of Defense will develop and expand a network of commercial facilities dedicated to the biomanufacture of products deemed critical for defense needs. This aims to secure supply chains and enhance domestic production capabilities for biotechnological defense applications.
Section 2(b)(2)
Incorporating Biotechnology into Military Specifications
The strategy must include a review and update of existing military specifications to better incorporate or substitute current products with biotechnology-based alternatives. This aims to modernize defense procurement and leverage advanced biological materials and processes.
Section 2(b)(3)
Policies for Advance Market Commitments and Offtake Agreements
The strategy must include updated plans and policies for the Department of Defense to enter into advance market commitments and offtake agreements for biotechnology products with defense applications. These mechanisms help de-risk investment for biotech companies by guaranteeing future purchases.
Section 2(b)(4)
Incorporating Biotechnology into Wargaming and Net Assessment
The strategy must describe how the Department of Defense can better incorporate military-relevant applications of emerging biotechnology into wargaming exercises, tabletop exercises, and other net assessment analyses. This aims to understand and prepare for future conflicts involving biotech capabilities.
Section 2(b)(5)
Feasibility of a Biotechnology Research Grand Challenge
The strategy must assess the benefits and costs of issuing a research grand challenge, or a series of challenges, focused on making biotechnology predictably engineerable. It also requires outlining how the Department would implement such challenges. This aims to accelerate fundamental research in biotech predictability.
Section 2(b)(6)
Developing a Biotechnology Regulation Science and Technology Program
The strategy must include the development of a biotechnology regulation science and technology program within the Department of Defense. This program would involve creating digital infrastructure to support simplified regulation and developing biometrology tools, aiming to streamline the regulatory process for defense-related biotech.
Section 2(b)(7) and (8)
Encouraging NATO Biotechnology Cooperation
The strategy must include updated plans and policies for the Department of Defense to provide inter-governmental support to encourage NATO member countries to aggregate demand and pool purchasing power for biotechnology products. Additionally, it requires a review of plans on how the DoD can work to develop, integrate, and disseminate biotechnology research initiatives across NATO members, coordinating combined research capabilities. This aims to strengthen allied biotech capabilities and interoperability.